Brokerages Set NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Target Price at $48.00

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have earned an average rating of “Moderate Buy” from the twelve research firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $48.00.

A number of research analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Wall Street Zen cut shares of NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Truist Financial began coverage on shares of NewAmsterdam Pharma in a report on Wednesday, March 18th. They set a “buy” rating and a $57.00 price objective on the stock. Needham & Company LLC raised their price objective on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $55.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th.

NewAmsterdam Pharma Trading Up 4.5%

Shares of NAMS stock opened at $34.68 on Wednesday. The stock has a market capitalization of $3.99 billion, a price-to-earnings ratio of -20.05 and a beta of 0.13. NewAmsterdam Pharma has a twelve month low of $15.82 and a twelve month high of $42.00. The stock has a fifty day simple moving average of $32.78 and a two-hundred day simple moving average of $34.48.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.92 million. Research analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Activity

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 104,467 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $30.30, for a total value of $3,165,350.10. Following the completion of the sale, the insider directly owned 69,302 shares in the company, valued at $2,099,850.60. This trade represents a 60.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Louis G. Lange sold 44,619 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $30.42, for a total transaction of $1,357,309.98. Following the completion of the transaction, the director directly owned 10,360 shares in the company, valued at $315,151.20. This represents a 81.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,313,286 shares of company stock worth $42,963,764 in the last quarter. 20.84% of the stock is currently owned by corporate insiders.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN boosted its holdings in NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after acquiring an additional 300 shares in the last quarter. Geode Capital Management LLC grew its position in NewAmsterdam Pharma by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock worth $3,590,000 after purchasing an additional 437 shares during the last quarter. Arizona State Retirement System increased its stake in NewAmsterdam Pharma by 3.8% during the 3rd quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $377,000 after purchasing an additional 483 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of NewAmsterdam Pharma by 2.4% in the second quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company’s stock worth $408,000 after buying an additional 521 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of NewAmsterdam Pharma by 5.3% during the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after buying an additional 544 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.